Business
Krystal Biotech Appoints Andy Orth as Chief Commercial Officer
PITTSBURGH, May 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases,
About this update from Krystal Biotech, Inc.
[{"type":"text","content":"PITTSBURGH, May 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, announced today the appointment of Andy Orth as Chief Commercial Officer. Mr. Orth has more than 25 years of global biotechnology experience, most recently in the role of Senior Vice President, Head of US Business at Alnylam Pharmaceuticals. “We are excited to welcome Andy to the Krystal team at such an exciting time for our lead investigational program B-VEC for DEB, and the rest of our growing rare disease pipeline,” said Krish S. Krishnan, chairman and chief executive officer of Krystal Biotech. “He is an accomplished biotechnology executive who has successfully launched several genetic medicines in the rare disease space and will be a key asset for Krystal as we work towards our goal of building a fully integrated biotechnology company with a strong commercial capability.” “I am thrilled to be joining Krystal and see tremendous potential in the innovative technology platform and rapidly maturing pipeline,” Andy commented. “I look forward to enhancing the commercial capabilities at Krystal to achieve our ultimate goal of bringing important medicines to patients in need.” In his role of Senior Vice President, Head of U.S. Region at Alnylam, Andy led the organization through multiple launches of rare disease genetic medicines and was responsible for leading the U.S. Business Account Teams, Market Access, Marketing, Patient Services and Operations. Previously, Andy served as Alnylam’s Vice President of Commercial Practice where he helped build out Alnylam’s global commercial capabilities. Prior to Alnylam, Andy held various roles across Commercial and Finance with Biogen, Genzyme and Amgen. Andy received his MBA from Cornell University and his undergraduate degree from the University of Wisconsin. About Krystal BiotechKrystal Biotech, Inc. (NASDAQ:KRYS) is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases. For more information, please visit http://www.krystalbio.com. Forward-Looking StatementsAny statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., including but not limited to statements about t...